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Summary
The development of a preventative HIV vaccine able to elicit broadly neutralizing an-
tibodies (bNAbs) remains a major challenge. Antibodies that recognize the V2 region 
at the apex of the HIV envelope trimer are among the most common bNAb specifici-
ties during chronic infection and many exhibit remarkable breadth and potency. 
Understanding the developmental pathway of these antibodies has provided insights 
into their precursors, and the viral strains that engage them, as well as defined how 
such antibodies mature to acquire breadth. V2- apex bNAbs are derived from rare pre-
cursors with long anionic CDR H3s that are often deleted in the B cell repertoire. 
However, longitudinal studies suggest that once engaged, these precursors contain 
many of the structural elements required for neutralization, and can rapidly acquire 
breadth through moderate levels of somatic hypermutation in response to emerging 
viral variants. These commonalities in the precursors and mechanism of neutralization 
have enabled the identification of viral strains that show enhanced reactivity for V2 
precursors from multiple donors, and may form the basis of germline targeting ap-
proaches. In parallel, new structural insights into the HIV trimer, the target of these 
quaternary antibodies, has created invaluable new opportunities for ontogeny- based 
immunogens designed to select for rare V2- bNAb precursors, and drive them toward 
breadth.
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1  | INTRODUCTION
The design of an effective preventative HIV vaccine continues to rep-
resent a major public health challenge, with 36 million people currently 
living with HIV. Despite more than 17 million people now access-
ing antiretroviral treatment globally and an array of prevention tools, 
new infections continue to occur at high rates, particularly in parts of 
southern Africa, with 2 million new infections estimated to occur annu-
ally. Many successful vaccines rely on the elicitation of neutralizing an-
tibodies to block viral entry and provide sterilizing protection. However, 
this is a particular challenge for HIV, which is among the most variable 
and heavily glycosylated viruses known. Several vaccines have been 
tested with little or no efficacy, and none of these vaccines have been 
able to elicit the types of broadly neutralizing antibodies (bNAbs) that 
will be required to be effective against the enormous global diversity 
of HIV. Despite these setbacks, there is strong rationale for pursuing This article is part of a series of reviews covering B cells and Immunity to HIV appearing in 
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bNAbs to prevent HIV infection. Passive immunization of bNAbs iso-
lated from infected donors has long been known to protect non- human 
primates from infection [reviewed in (1)]. Indeed, a recent study showed 
that a single injection of bNAbs protected animals against repeated ex-
posure for up to 23 weeks.2 Furthermore, studies of HIV infected do-
nors have shown that the human immune system has the capacity to 
make such bNAbs. These findings, along with the failure of traditional 
vaccine strategies, has led the field to consider next- generation vaccine 
regimens which are based on detailed studies of the ontogeny of bNAbs 
during infection, a strategy referred to as the B cell lineage approach.3 
Here, we describe recent virological, immunological, and structural 
studies supporting and informing this approach, specifically focusing on 
bNAbs that target the V2 region at the apex of the envelope trimer.
2  | WHY IS V2 AN ATTRACTIVE BNAB 
VACCINE TARGET?
The HIV- 1 envelope (Env) glycoprotein complex, which consists of 
a heterotrimer of three molecules of gp120 and three molecules of 
gp41, is responsible for mediating viral entry into host cells, and is 
the sole target of neutralizing antibodies. The first and second vari-
able  regions (V1V2) of gp120 are located at the apex of the envelope 
trimer, and are highly variable in terms of sequence, glycosylation and 
length, largely due to mutations and insertions in two regions, in the 
middle of V1 and toward the C- terminal end of V2 (Figure 1). In con-
trast, semi- conserved regions exist, particularly in the V2 region which 
is the focus of this review, in strands B and C, including highly con-
served glycans at positions 156 and 160 and other fairly conserved 
residues such as those 166 and 169, which will be described in further 
detail below. The V1V2 domain is an important contributor to viral 
entry and neutralization resistance of HIV isolates [reviewed in (4)]. 
Studies of transmission pairs suggest that in many cases infection is 
mediated by viruses with compact V1V2 regions, which subsequently 
become longer during the course of infection, suggesting a complex 
interplay between infectivity and the need for neutralization resist-
ance through V1V2 sequence changes, elongation and glycosyla-
tion. The role of the V1V2 region in immune evasion is emphasized 
by the extreme neutralization sensitivity of V1V2- deleted viruses.5–9 
F IGURE  1 Global alignment and trimeric location of V1V2 within the envelope trimer. (A) Logogram illustrating the amino acid profile of 
the 2015 version of the LANL premade alignment for Group M V1V2 envelope sequences. The size of each amino acid in the profile indicates 
prevalence of that amino acid in global sequences. The V1V2 sequence of HXB2 is placed below the profile. Beta strands and strand- connecting 
loops (SCLA-B and SCLC-D) are illustrated by arrows and dashed lines respectively. Modified from (58) (B) Side view ribbon representation of 
the HIV envelope trimer, highlighting the location of the V1V2 domain at the trimer apex. The five anti- parallel beta strands (beta- barrel) are 
shown in purple, while stick and surface representations of the N156 and N160 glycans are shown in cyan and blue respectively. Key amino 
acid residues at position 166 and 169 are shown as spheres in green and orange respectively. The approximate position of the viral membrane 
is indicated. (C) Ribbon representation of the trimer showing the view from the angle of approach by V2- apex bNAbs. PDB ID: 4TVP. N- linked 
glycans were modeled using http://www.glycosciences.de/modeling/glyprot/php/main.php
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The V1V2 region is itself a frequent target of neutralizing antibod-
ies that drive viral escape mutations within this region.10–15 In some 
cases, multiple unrelated B cell lineages target this region, highlighting 
the  immunogenicity of V1V2 during infection.10 The high variability 
in this region results in the majority of these autologous neutralizing 
responses being strain- specific and easy for the virus to evade, pro-
viding limited insights for HIV vaccine design. However, within this 
region, the semi- conserved elements of V2 may also be the target of 
bNAbs able to recognize diverse circulating viruses, and these are the 
basis of this review. Thus, while the V1V2 region has long been recog-
nized as a target for antibodies, it was only in 2009 with the isolation 
of the bNAbs PG9/PG16 that its relevance for vaccine design was 
truly appreciated.
While almost all infected people develop antibodies to the HIV en-
velope which have some cross- neutralizing activity,16 only about 20%- 
30% of people develop responses that are considered truly broadly 
neutralizing.17–20 Several factors have been associated with the de-
velopment of bNAbs during infection, including various measures of 
germinal center T cell function,17, 19–27 low CD4+ counts,17, 18 HLA and 
viral subtype.18 In addition, several cohort studies have shown that a 
major contributor to the development of bNAbs is high levels of an-
tigenic stimulation, in the form of high viral loads and duration of in-
fection,19, 20, 28 though there are occasional reports of viral controllers 
who nonetheless mount bNAb responses.29 BNAbs normally emerge 
only several years after infection, and frequently have unusual features 
that are not favored by the immune system, including autoreactivity, 
very long or short CDRs depending on the class of antibodies and high 
levels of somatic hypermutation (SHM), in some cases >30%.1 The 
association with duration of infection and the high levels of SHM of 
many HIV bNAbs suggest a long co- evolutionary pathway, requiring 
variation in both the virus and the antibody. Indeed, two recent stud-
ies suggest that bNAb lineages evolve as quickly as HIV, particularly 
during the early stages of their development, though these rates later 
decline.30,31 This suggests that even during infection in the context of 
high levels of viral replication and antigenic stimulation, the develop-
ment of bNAbs is a difficult pathway. These challenges in developing 
bNAbs are obviously even greater in the context of vaccination, where 
antigenic stimulation is normally limited to two or three immunogen 
exposures, and SHM is normally restricted to about 6%.32
Despite these impediments to bNAb development, much of the 
surface of the HIV trimer is now known to be vulnerable to bNAbs, 
with many antibody epitopes including the glycans that provide half of 
the molecular weight of the HIV envelope, and were initially assumed 
to function solely as a shield for underlying epitopes.33, 34 These find-
ings come from the isolation of dozens of broadly neutralizing mono-
clonal antibodies,35, 36 largely due to the optimization of relatively new 
technologies for human antibody isolation including antigen- specific 
sorting (most recently using trimeric antigens which are particularly 
important for the quaternary V2- apex bNAbs37,38), B cell culture with 
micro- neutralization assays for screening of individual wells, and mul-
tiplex RT- PCR for amplifying immunoglobulin genes from single cells 
[reviewed in (35, 39, 40)]. Characterization of these new bNAbs has 
enabled the field to define several conserved viral epitopes including 
the V2- apex site that is the focus of this review, as well as the N332 
glycan supersite, the membrane proximal external region (MPER), the 
CD4 binding site (CD4bs), and the gp120- gp41 interface, recently 
shown to include the fusion peptide.33, 41 Although many vaccine 
strategies aim to elicit a polyclonal response that would ideally target 
multiple conserved epitopes, several approaches are target- specific. 
The use of strategies such as minimal epitopes, and have thus resulted 
in a concerted effort to understand the breadth of antibodies to spe-
cific epitopes such as the V2- apex.
Antibodies to the V2- apex may be especially attractive from a 
vaccine perspective because they are among the most prevalent of 
broadly neutralizing responses, with mapping studies in several co-
horts of infected donors showing that these account for up to a third 
of bNAb responses.17, 18, 42–44 This indicates that the immune system 
of many individuals is amenable to the development of these specific-
ities. Furthermore, monoclonal antibodies (mAbs) to this epitope have 
been isolated from several donors (PG9/PG16 from donor IAVI24, 
the CH01- 04 lineage from donor CH0219, the PGT145/PGDM1400 
lineage from IAVI84, and the CAP256- VRC26 lineage from CAP256) 
enabling a comprehensive understanding of their features and neu-
tralization capacity37, 38, 45–47 (Table 1 and Figure 2). These mAbs all 
have structural properties in common, such as an unusually long CDR 
H3 loop that is generally highly anionic. This negative CDR H3 charge 
is provided both by an abundance of aspartate and glutamate resi-
dues, and by sulfation of tyrosines, and facilitates recognition of the 
positively charged V2 epitope through a shared mode of recognition, 
described below (Figure 2).
These mAbs often have substantial breadth, neutralizing 70%- 
85% of viruses,38, 46, 48 and in some cases remarkable neutralization 
potency in the nanomolar range.37, 38, 46, 47 The need to understand 
future vaccine coverage, and more immediately the potential util-
ity of mAbs in passive immunization, has led to studies using large 
panels of transmitted/founder viruses (the infecting virus that both 
active or passive immunization strategies will need to block) and 
assessed which combinations of bNAbs may provide optimal po-
tential clinical benefit.48,49 In one such study, a V2- apex antibody, 
CAP256- VRC26.25 was included in both the best 2- mAb and 3- mAb 
combinations, highlighting the potential of this specificity in passive 
immunization, but also in vaccine- elicited responses. Similarly, a com-
bination of V2- directed PGDM1400 with PGT121 (which targets the 
N332  supersite) has been shown to achieve extraordinary breadth 
and potency,  neutralizing 98% of that particular panel of viruses at a 
median IC50 of 0.007 μg/mL.
38 Although the breadth of some individ-
ual CD4bs mAbs and MPER antibodies exceeds those of V2- directed 
broad antibodies, their high levels of SHM and (in the latter case) lipid 
reactivity and autoreactivity may suggest difficulties in their elicitation 
by vaccination. In contrast, V2- apex antibodies may acquire breadth 
with moderate levels of SHM, often as little as 15% divergent from 
their unmutated common ancestor (UCA)47 (Table 1).
Interest in the V2 region has further increased since the findings 
of the RV144 vaccine trial, a canary- pox prime and gp120 protein 
boost regimen that was tested in Thailand in 2009, and which showed 
moderate efficacy of 31%.50 A subsequent immune correlates analysis 
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showed that vaccine- induced IgG against V1V2 was inversely cor-
related with risk of HIV acquisition,51 a finding supported by a “sieve 
analysis” that showed immune pressure in V2 in viruses infecting vac-
cine recipients52 and by several follow- up studies [reviewed in (53)]. 
However, although such antibodies were able to mediate antibody- 
dependent cellular cytotoxicity and virus capture, there is no evidence 
that the low level protection observed during the RV144 vaccine 
trial was mediated through neutralization. Nonetheless, RV144 has 
spawned a wide array of immunologic studies, and follow- up vaccine 
trials such as those currently underway in sub- Saharan Africa in the 
HVTN 702 trial to test HIV- 1 subtype C tailored equivalents. These 
trials will undoubtedly continue to reveal insights into the role of non- 
neutralizing antibodies to V1V2 and under- appreciated effector func-
tions of antibodies in HIV vaccine efficacy.
3  | STRUCTURAL INSIGHTS INTO V2- APEX 
ANTIBODY MEDIATED NEUTRALIZATION
The failure of empirical vaccine approaches for HIV has led to an in-
creased dependence on more structure- based approaches to immuno-
gen design. Studies of HIV envelope structural biology have provided 
key insights into the HIV- 1 envelope and broadly neutralizing anti-
bodies, including V2- directed antibodies, that are able to circumvent 
its considerable defenses. A crystal structure of the HIV- 1 envelope 
gp120 core was solved in 1998, and provided the first atomic- level 
details of the HIV- 1 Env.54 This core construct, however, lacked the 
V1V2 domain (residues 126- 196, HXB2 numbering), which resisted 
crystallization for another 13 years. A critical breakthrough in deter-
mining the structure of the conformationally variable and highly glyco-
sylated V1V2 domain came through the isolation of glycan- dependent 
broadly neutralizing antibodies, such as mAb PG9/PG16 that bound 
V1V2 only in its native form.46 These antibodies led, in 2011, to the 
first crystal structures of the V1V2 domain, which were achieved using 
scaffolded constructs, with the V1V2 region engrafted onto a heter-
ologous protein, bound to PG955 (Figure 3A). Importantly, the recently 
discovered V1V2- directed bNAbs enabled an “on- column” method, 
where mAbs were coupled to the column and used to specifically 
purify properly folded and glycosylated V1V2 scaffolds. Viral strains 
ZM109 and CAP45, both clade C viruses, were solved at 1.8 Å and 
2.2 Å respectively. The structures not only revealed atomic- level de-
tails regarding the neutralization mechanism of PG9 but also provided 
the first glimpse at the two variable domains that cap the trimeric viral 
envelope. V1V2 was shown to comprise a four stranded beta- sheet 
with disordered loops between strands A and B and strands C and 
D, and later structures would reveal an additional strand not seen in 
the initial scaffolded structures due to dimerization of the V1V2 do-
mains.56–58 Although, as described above, V1V2 had long been recog-
nized as a highly variable region, the sequence elements comprising 
the strands of the domain are more conserved than the outer loop re-
gions (Figure 1A). The unusually long CDR H3 engaged strand C of V2 
through main- chain interactions forming a parallel β- strand along the 
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side- chain interactions with this positively charged region buried under 
the glycan shield. Although the C- strand of V2 is more conserved than 
the loop regions, the sequence variations that do exist could be better 
tolerated due to the CDR H3 main- chain interactions with the peptide 
backbone, which is largely sequence- independent, providing a mecha-
nism for breadth among antibodies targeting this site.
PG9- bound V1V2 revealed how bNAbs could target this region 
not only by penetrating the glycan shield, but by using the dense array 
of glycans, typically regarded as a viral defense, as part of their epi-
tope. PG9 neutralization is dependent upon glycans at residues N156 
(or N173 in some strains) and N160, with the latter conserved gly-
can being critical for recognition (Figure 3A). The scaffolded proteins 
in the crystal structures were grown in HEK293S GnTI− cells, which 
lack N- acetylglucosaminyltransferase I activity, trapping the glyco-
sylation pathway at an early stage. On- column purification further 
selected scaffolds with glycosylation profiles favorable to PG9 bind-
ing, Man5GlcNAc2 (Man5) glycans at N156 and N160. ZM109 falls 
among a minority of HIV- 1 strains that do not have a glycan at N156 
but instead contains a glycan at residue N173, which is in close three- 
dimensional proximity to N156 in the structure and serves as a viable 
substitute. The co- crystal structure of PG16 with a scaffolded V1V2 
domain from ZM109, grown in cells treated with the α- mannosidase II 
inhibitor swainsonine (predicted to induce hybrid- type glycans), high-
lighted a difference in glycan specificity for this clonal relative of PG9. 
These preferences suggest that while glycans at residues N156/N173 
and N160 may primarily consist of Man5,60 they are not completely 
homogeneous and that antibody lineages differentiate to accom-
modate various glycoforms, as has been observed also for glycan- 
targeting bNAb specificities to other conserved sites.61
Comparison of V2- apex targeting bNAbs with non- broadly neutral-
izing antibodies that target this same region has also yielded useful in-
formation. Sieve analysis during the RV144 vaccine trial had detected 
immune signatures at sites 169 (an important part of bNAb epitopes) 
and residue 181. This was supported by the isolation of two V2- 
directed antibodies, called CH58 and CH59, both isolated from RV144 
vaccines. These antibodies, despite apparently targeting conserved el-
ements of V2, did not display broadly neutralizing activity.62 Co- crystal 
structures of these vaccine- elicited antibodies with a peptide from the 
V1V2 domain corresponding to the C- strand revealed that these an-
tibodies bound to helical and loop conformations considerably differ-
ent from those seen in the scaffolded structures (Figure 3B). Surface 
Plasmon Resonance assays with these antibodies and PG9 confirmed 
that within a population of monomeric gp120s, the C- strand of V1V2 
could adopt multiple conformations, each recognized by a different 
F IGURE  2 Broadly neutralizing V1V2- directed antibodies share common structural features. Fabs for prototypical members of each lineage 
are presented in cartoon representation. Unusually long CDR H3s protrude beyond the framework region (upper row). The CDR H3 regions are 
shown close up as cartoon with sulfated tyrosines displayed as sticks. Electrostatic charge is shown depicted on the surface to the right of each 
cartoon representation (second row). Antibodies are shown in the trimer context with 3D EM reconstructions for PG9 and CAP256.09, 2D EM 
class average for PGDM1400, and an alignment to trimer model for CH03 (row 3). Lineages from each donor show a binding stoichiometry of 
one fab per trimer. PGDM1400 engages as a steeper angle down the center of the threefold axis rather than off- center as observed for other 
V1V2 bNAbs. Crystal structures of PG9 and CH03 highlight atomic- level detail of antibody binding. CAP256.25 atomic interactions are modeled 
based on EM, MD, HDX and paratope mapping. PGT145/PGDM1400 atomic level details are unknown but data suggest binding differs from 
other members of this extended class (bottom row)
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antibody. These data highlighted the immunologically defensive con-
formational flexibility of this region, with monomeric gp120, used in 
the vaccine trial and in ongoing trials, less likely to remain in the con-
formation recognized by broadly neutralizing antibodies than closed 
native trimer. Isolation of a similar antibody from a subtype C HIV in-
fected donor suggests that such antibodies are elicited during infec-
tion too (C. Van Eeden, L. Morris et al., unpublished data). Isolation of 
additional non- broad V2 antibodies after vaccination and infection is 
likely to provide further information regarding the proportion of V2- 
targeting antibodies that have the potential to mature towards breadth.
4  | ELUCIDATING THE TRIMER 
STRUCTURE PROVIDES NEW TOOLS FOR 
IMMUNOGEN DESIGN
Broadly neutralizing antibodies that target the V2 region prefer or re-
quire a quaternary epitope,45–47 which has complicated attempts to 
elicit such antibodies. The establishment of a soluble prefusion closed 
trimer 63 enabled these antibodies targeting the trimer interface at the 
apex of the viral spike to be imaged by negative stain electron micros-
copy (EM). The first structure, a three- dimensional reconstruction of 
PG9 in complex with an engineered trimeric envelope called BG505 
SOSIP.664, provided a clue as to the quaternary nature of these anti-
bodies.64 PG9 bound asymmetrically to the cap of the spike with a sto-
ichiometry of a single Fab per trimer (Figure 3C). Using the threefold 
symmetry of the Env and fitting the previously determined scaffolded 
complex crystal structure with PG9, the authors suggested that PG9 
likely would interact with the N156 (or N173) and N160 glycans of 
the bound protomer, but would likely also bind the N160 glycan of a 
neighboring protomer (Figure 3C). A second EM structure was deter-
mined with CAP256- VRC26.09 bound to a BG505 SOSIP.664 trimer 
and showed a similar result to that of PG9.47 Analysis of a third anti-
body, PGDM1400, by EM with 2D class averages revealed that this 
antibody bound closer to the center of the threefold axis than the 
previous two, suggesting it may bind in a different manner.38
F IGURE  3 Structural advances in 
definition of the V1V2 epitope. (A) Crystal 
structures of monomeric scaffolded- 
V1V2 bound by PG9 laid the foundation 
for the structural definition of the V1V2 
domain. PG16 bound to the same scaffold 
with an alternate glycoform highlighted 
the specificity of lineage members to 
heterogeneity in the glycan shield. (B) 
CH58 and CH59, antibodies isolated from 
an RV144 vaccine that do not neutralize 
tier 2 virus, were crystallized with a V2 
peptide. These structures, together with 
Surface Plasmon Resonance data, revealed 
that the C- strand of V1V2 adopts multiple 
conformations on monomeric gp120, 
masking the broadly neutralized epitope. 
(C) EM of PG9 in complex with the trimeric 
BG505 SOSIP.664 together with high- 
resolution crystal complexes suggests that 
the quaternary preference of PG9 is a 
consequence of binding the N160 glycan of 
the neighboring protomer. (D) The crystal 
structure of CH03 bound to a trimeric 
V1V2 scaffold confirms a strong interaction 
with the neighboring N160 glycan in 
addition to the N160 of the primary- bound 
protomer. (E) Multiple crystal structures 
of trimeric Env (SOSIP.664) define the full 
quaternary epitope of V1V2, which has 
protective glycans at N156 and N160 and 
is positively charged
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Insights into the quaternary requirements for V2- directed bNAbs 
and difficulty with crystallizing an asymmetric complex (containing 1 
Fab per trimer) led to the screening of trimeric scaffolded V1V2 pro-
teins as tools for crystallization to understand the atomic- level details 
of lineages other than PG9/PG16. Through ELISA screening on V1V2 
trimeric scaffolds in a 96 well format, a scaffold that bound to V2 bNAbs 
better than monomeric gp120s was identified. A 3.1 Å structure of 
CH03 (from donor CH0219) on a trimeric V1V2 scaffold, derived from 
the virus that superinfected donor CAP256 (described in more detail 
below), showed a very similar mechanism of engagement to that of 
PG957 (Figure 3D). Both antibodies bound the C- strand through main- 
chain strand- strand hydrogen bonds, though PG9 also showed more 
involved side chain interactions. Both antibodies also bound glycans 
at N156/N173 and N160. The CH03 structure, however, revealed a 
glycan interaction not seen in the monomeric structures. Although the 
orientation of the V1V2 domains in the trimeric scaffold differed from 
that of the native spike, a glycan from a neighboring protomer, in close 
proximity to the position of the N160 of a neighboring protomer on 
the native trimer, bound extensively to CH03 (Figure 3D). This qua-
ternary glycan interaction provided the experimental atomic details to 
support the hypothesis put forward in the PG9- BG505 SOSIP.664 EM 
study described above.57 Although an Env- complexed crystal struc-
ture remains elusive for the CAP256- VRC26 lineage, data from EM, 
hydrogen- deuterium exchange, molecular dynamics, and  mutagenesis 
studies all suggest that these antibodies engage the V2 domain through 
a similar mechanism as PG9/PG16 and CH01- CH04.57 The isolation of 
these similar formed antibody lineages from multiple  donors suggests 
the existence of an extended class of antibodies.
Since V2- directed antibodies prefer or require a quaternary epi-
tope, advances in the construction of a soluble trimeric molecule that 
recapitulates the architecture of the native trimeric viral spike were 
critical to understanding the nature of the epitope. A crystal structure 
and high resolution EM structure of BG505 SOSIP.66464, 65 provided 
great insight into the details of the epitope. Although the approximate 
trimeric interface could be calculated from the earlier low- resolution 
EM and crystal structures together, the exact details that are critical 
for immunogen design against this region were not known. Although 
the resolution limited details of the side chains, the structures con-
firmed that the scaffolded V1V2 domain seen in complex with PG9 
and PG16 recapitulated the overall domain structure in the near- 
native closed trimeric conformation (Figure 3E). A higher resolution 
structure56 would later provide greater details, including a fifth strand 
(C′) not previously seen. The trimeric orientation of V1V2 results in a 
highly positive region at the apex of the spike that is targeted by the 
anionic CDR H3 of V2- directed bNAbs (Figure 3E, right panel). Recent 
fully glycosylated trimer crystal structures reveal the protective nature 
of the glycan shield at the apex of the spike.66 The extensive glycan 
coverage requires antibodies targeting the semi- conserved C- strand 
region of V2 to have long CDR H3 in order to penetrate through small 
crevices to interact with the protein surface. This recent establish-
ment of soluble trimers has thus provided a wealth of information for 
 quaternary epitopes, V2 specifically, and creates an exciting tool for 
understanding antibody development and vaccine design.
5  | THE ANTIBODY PRECURSORS AND 
VIRAL TRIGGERS OF V2- APEX LINEAGES
Studies of the ontogeny of other classes of bNAbs have proven 
to be extremely revealing. In particular the shared germline gene 
structures and predictable developmental pathways for the CD4 
 binding site (CD4bs) class of bNAbs have enabled great progress in 
the  development of germline targeting immunogens for this class 
 (reviewed elsewhere in this series). Similar studies have recently been 
performed for V2- apex antibodies, which based on commonalities in 
structure (and ontogeny, described in more detail below) have been 
proposed to form an “extended class” of antibodies57 (Figure 4).
Such studies rely on the comparison of V2- apex antibodies from 
multiple donors. The majority of V2 bNAbs were isolated from donors 
during chronic infection, but despite the absence of early sequences 
from these antibody lineages, have proved highly informative. For 
the PG9/PG16 mAbs, little additional lineage information is available 
and approximations of early members can only be calculated through 
comparison of the two antibodies and their germline VH/VL genes. In 
these constructs, the VH or the VH and VJ gene segments are replaced 
by the corresponding germline genes, however, the CDR H3, a major 
determinant of neutralization, which spans the V- D- J junction, cannot 
be accurately reverted and is left as the mature form. These germline 
reverted constructs (referred to as gHgL or reverted unmutated an-
cestors, RUAs) approximate the properties of a true UCA as well as 
possible. One version of the reverted PG9 gHgL bound to eight tri-
meric envelope strains in an ELISA format and neutralized four of 182 
strains.57 However, PG9 gHgL with one additional amino acid rever-
sion in the CDR H3 failed to induce Ca flux in a B cell activation exper-
iment which included strain ZM233,67 one of the four strains shown to 
be neutralized by the first revertant,57 highlighting the importance of 
accurately determining the CDR H3 for this class of antibody.
Similarly for CH01- CH04, two versions of a putative precursor 
(RUA- 1 and RUA- 2) were inferred from the complete sequences of 
the four lineage members (CH01- CH04) isolated from donor CH0219 
during chronic infection.68 They differ by one amino acid in the CDR 
H3 due to an uncertainty in one non- synonymous position (G/T at 
position 401 in the CDR H3) of the calculated ancestor. These variants 
contain fully reverted VH and VL genes, however, the CDR H3s differ 
from the most closely related mature lineage members by only one or 
two amino acids for RUA- 1 and RUA- 2 respectively. These two CH04 
early ancestors neutralized four of 24 tier 2 viruses (i.e. neutraliza-
tion resistant viruses that represent circulating strains) in one study17 
and RUA- 2 neutralized nine of 201 in a second.57 Next generation 
sequencing (NGS) data of donor CH0219 was later obtained and indi-
cated that the earliest inferred ancestor, which had a maturation rate 
of only 0.3%, differed by two amino acids in the CDR H3 from the pre-
viously defined RUA- 1 or RUA- 2, with one change located at the pre-
viously uncertain position.57 Notably, these residues (100e and 100f, 
Kabat numbering) reside in an area of direct contact with V2, although 
they form hydrogen bonds through main- chain strand- strand interac-
tions, which may limit the impact of the side chains in this region.
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The same approach was taken with the PGT145/PGDM1400 lin-
eage isolated from donor IAVI84, which differs slightly from the other 
V2 bNAbs as its CDR H3 is extended at less of an angle and the ap-
proach of the antibody to the V2 domain is more centered. Given this, 
the exact binding mode may differ from the other V2 bNAbs, however, 
it shares the same genetic characteristics observed in the others. The 
CDR H3s of most members are 32 residues in length although some, 
including PGT145, contain a single amino acid deletion. Intradonor 
phylogenetic analysis of sequences from the mature isolated antibod-
ies as well as NGS data revealed the earliest intermediate that could 
be well- defined still had ~6% nucleotide- level SHM. The CDR H3 had 
32 amino acids and a net −5 charge, and did not include sulfated tyro-
sines, suggesting that many of the determinants of the canonical long, 
anionic CDR H3 were formed early in the lineage.
Of all the V2 bNAb lineages, only the CAP256- VRC26 family iso-
lated from a subtype C infected and superinfected donor has been 
characterized longitudinally from the time of infection, providing key 
insights that support and extend the studies described above. The 
earliest cloned antibody, CAP256- VRC26.01, was isolated at week 59 
and 32 other members of the lineage were isolated at weeks 119- 
206 by a combination of B cell culture and trimer- based sorting.37, 47 
NGS was performed at multiple time points to pinpoint when the 
lineage emerged. At 15 and 30 weeks postinfection, no CAP256- 
VRC26 lineage- related sequences were observed out of ~250,000 
sequence reads. However, at week 34 and later time points, hundreds 
to thousands of lineage sequences were observed.47, 69 Using the NGS 
sequences as well as the cloned antibody sequences, a maximum like-
lihood phylogenetic analysis was used to infer the UCA.47 Sequences 
that differed from the UCA by only a few nucleotides were found in 
the week 34 and week 38 data, supporting the accuracy of the UCA 
inference. The reconstructed UCA was able to bind to a trimeric Env 
spike mimic that bears the V1V2 of the superinfecting transmitted/
founder strain CAP256- SU57 and weakly neutralized the superinfect-
ing virus41 consistent with the fact that the bNAb response predom-
inantly targeted this viral strain. Thus, the UCA had the key properties 
of the lineage, with an anionic CDR H3 of 35 amino acids formed in 
the original VDJ recombination event, rather than a gradual extension 
by SHM, but required engagement by an unusual viral envelope (see 
below).
6  | TRIGGERING PRECURSORS OF  
V2- APEX LINEAGES
The long CDR H3s that characterize V2- apex antibodies range from 
24- 37 amino acids (Kabat numbering). These are in contrast with typi-
cal antibodies, which have a mean length of 14- 16 amino acids.70–73 
Antibodies with such long CDR H3s are relatively rare - those with CDR 
H3s longer than 24 amino acids comprise only 3.5% of the naïve rep-
ertoire while CDR H3s longer than 28 amino acids are only present in 
0.43% of native B cells. Notably, CDR H3s longer than 24 amino acids 
are significantly more common in the naïve repertoire than in mature B 
cells (in both the IgG and IgM memory subset), possibly due to autore-
activity and deletion at checkpoints,74, 75 posing an additional challenge 
to eliciting such responses. Antibodies with long CDR H3s tend to be 
enriched for the use of a subset of D and J gene segments,75 which are 
associated with conserved sequence motifs. These motifs include the 
tyrosine- sulfated YYD motif seen in both PG9/16 and CAP256- VRC26 
lineage members that contributes to the anionic nature of the CDR 
H3, though its precise role in epitope recognition differs between the 
two antibodies.57 The use of two tandem D genes, termed D- D fusion, 
may also contribute to long CDR H3s,76 although this unlikely to be the 
source of the ultra- long CAP256- VRC26 CDR H3.47 Despite these low 
frequencies, in the context of between 1010 and 1011 B cells in vivo, it 
is likely that as for other rare bNAb precursors,77 sufficient numbers of 
V2 apex precursors exist in the naïve repertoire to be reliably recruited 
by an efficient germline- targeting immunogen.
Studying the neutralization and envelope binding profiles of V2- 
apex antibody precursors may provide clues as to the nature of the 
bNAb- initiating virus that triggered these lineages. Overall, studies of 
CAP256 and of other lineages suggest that V2- apex UCAs are unusual 
clones selected from the naïve repertoire, which do not neutralize or 
F IGURE  4 Schematic of B cell ontogeny 
of the V2- apex extended class of broadly 
neutralizing antibodies from four donors. 
Long, negatively charged CDR H3s are 
established during immunoglobulin gene 
recombination, forming progenitor B cells. 
Unusual viral variants with weak antigen 
affinity select these rare precursors, 
which mature to acquire breadth with 
moderate levels of somatic hypermutation. 
Mature bNAbs share a common mode of 
recognition of the HIV- 1 envelope trimer, 
with many determinants of neutralization 
present in the unmutated common 
ancestor. Figure adapted from Zhou et al.90
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bind the vast majority of strains. Indeed, in CAP256 for which the most 
accurate V2- apex precursor has been determined, the UCA neutral-
ized only the superinfecting transmitted/founder virus, but not the pri-
mary transmitted/founder virus or any other virus from a panel of two 
hundred.69 Identifying the virus that triggered the lineage was there-
fore a major interest, especially given that the CAP256- VRC26 lineage 
was detected only 20 weeks after superinfection.47,69 NGS of the viral 
V2 region revealed variability by week 34 (the first time point at which 
CAP256- VRC26 transcripts were detected) with descendants of both 
the primary and superinfecting viruses and recombinants thereof all 
represented. Three Env variants isolated from week 34 and derived 
from the superinfecting virus were more sensitive to neutralization by 
the UCA than the parental CAP256- SU virus, suggesting that they or 
similar bNAb- initiating envelopes engaged the B cell bearing the UCA, 
thereby triggering the lineage.69
Identifying additional such V2- apex bNAb- initiating envelopes 
has potential utility for immunogen design, but relies on detailed 
longitudinal sampling, and on these envelopes being generally more 
reactive with multi- donor V2- apex precursors than other viral enve-
lopes. Previous studies of V2- apex antibodies had sought to identify 
germline- reactive envelopes for individual lineages as the basis of fu-
ture immunogens.68 To empirically determine strains that may inher-
ently offer the most promising combinations of attributes sought in a 
V2 immunogen, large panel neutralization assays were carried out with 
mature, intermediate and germline reverted V2 bNAb antibodies from 
all four known donors. Where longitudinal data were available, UCAs 
were used, and otherwise V- gene reverted variants with mature CDR 
H3s served as approximate earliest ancestors.57, 68, 78 Notably, only a 
small number of stains were neutralized by these V2 bNAb precursors, 
with several of the strains such as WITO.33 and ZM233 overlapping 
between V2- bNAb donors.57 A parallel independent study also iden-
tified some of the same strains using a similar approach.79 Although 
each strain individually showed some traits to set them apart from the 
consensus, no universal particular elements could be detected among 
the sensitive strains. Interestingly, one of these strains included the 
CAP256 superinfecting virus (CAP256- SU), a variant of which elicited 
the CAP256- VRC26 lineage,69 highlighting the potential utility of lon-
gitudinal studies of V2- apex donors in identifying additional useful 
viral strains for inclusion into immunogens described in more detail 
below.
7  | MATURATION OF BREADTH FROM 
BNAB PRECURSORS
Beyond the initial engagement of precursors with long CDR H3, a 
key recent focus has been on how V2- apex antibodies (and other 
bNAb specificities) mature to acquire breadth. Longitudinal analyses 
of both antibody and virus during maturation of the CAP256- VRC26 
lineage have highlighted the substantial role of viral diversification in 
the emergence of neutralization breadth.47, 69 Phylogenetic analysis 
of the CAP256- VRC26 lineage shows two main branches. The first 
branch is thought to be an evolutionary dead end, in that members of 
the branch could not be detected among B cell transcripts from time 
points after week 119. In contrast, the second sublineage continued 
to evolve, with sequences observed at all time points up to 206 weeks 
postinfection. Affinity maturation that enabled progressively better 
binding and neutralization was largely in the CDR H3.47 This included 
a signature sequence that emerged early in the development of the 
second branch: a cysteine- cysteine disulfide bond in the CDR H3, 
along with an arginine at the base of the CDR H3, which may have 
stabilized the conformation of the CDR H3 and enhanced neutraliza-
tion breadth and potency.47
Comparison of the neutralization capacity of mAbs isolated from 
both branches against longitudinally sampled autologous viruses pro-
vided a mechanism for these distinct evolutionary outcomes. The 
antibodies in the “dead- end” branch were unable to tolerate viral es-
cape mutations that were selected as the viral quasispecies evolved 
to evade the early bNAb responses69 and were therefore no longer 
selected for. Such dead- end antibodies may be the reason for the 
rapid loss of lineage transcripts observed for several bNAb lineages.80 
In contrast, within the second branch, increasing breadth of mAbs was 
shown to be correlated with a capacity to neutralize viral escape vari-
ants (termed “immunotypes”) at positions 166 and 169 in the C- strand 
suggesting that continued adaptation to emerging viral variants con-
tributed to the development of breadth.69 Similar findings and viral 
escape pathways have been observed for another V2- apex donor for 
whom longitudinal data are available (E. Landais and P. Poignard, un-
published). Interestingly, within this continually evolving CAP256 sub-
lineage, antibodies with both broad and narrow neutralization breadth 
were intermingled within the phylogenetic tree. This clustering of 
broad and narrow lineage members suggests that individual amino 
acid changes, rather than overall sequence identity, have large effects 
on neutralization capacity. Indeed, although many of the broader 
members of the lineage had high levels of affinity maturation, equally 
mutated but strain- specific antibodies, termed “off- track antibodies” 
were also detected in the lineage (Figure 5A), with similar observations 
reported for the PGT145/PGDM lineage and for bNAb lineages target-
ing other epitopes.38, 45, 80, 81 These observations suggest that somatic 
antibody variants with a variety of neutralization capacities frequently 
evolve side- by- side during chronic HIV infection (Figure 5A). This evo-
lution is likely to be driven by the concurrent diversification of the viral 
quasispecies: while some antibody mutations may improve the bind-
ing to specific autologous viral variants encountered in the germinal 
center, these may not be the same mutations that improve neutraliza-
tion breadth against heterologous viruses (which the antibodies never 
encounter). For example, some off- track antibodies in the CAP256- 
VRC26 lineage appear to target an immunotype among the circulating 
autologous viral quasispecies that is rare in globally circulating viral 
strains, likely accounting for the strain- specificity of that antibody (D. 
Sacks, P.L. Moore et al., unpublished).
These studies of bNAb maturation in donor CAP256 have defined 
a mechanism for how accumulating viral variants contributed to V2- 
apex bNAb development. Viral escape from early members of the 
antibody lineage creates multiple viral immunotypes. In parallel, SHM 
generates antibodies with differential abilities to engage these epitope 
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variants. Those antibody sublineages that are able to tolerate variabil-
ity at key epitope contacts may develop breadth. These findings have 
implications for ontogeny- based immunogen design, suggesting that 
breadth may require the incorporation of multiple immunotypes into 
vaccines, to drive antibody maturation toward tolerance of diversity69 
(Figure 5B). Ideally, B cell- lineage based vaccine strategies would aim 
to drive maturation of bNAbs, while limiting the loss of B cells that 
are unable to tolerate immunogen diversity and also avoiding off- track 
antibodies. Realistically, the stochastic nature of antibody maturation 
is likely to make this impossible. However, in the context of infection, 
dead- end and off- track antibodies in many donors do not appear to 
hinder the development of breadth, a scenario supported by modeling 
of germinal center reactions in the context of cocktails of immunogens 
(J.S. Shaffer and A.K. Chakraborty, unpublished).
8  | INCORPORATING ONTOGENY INTO 
STRUCTURE- BASED IMMUNOGEN DESIGN
Studies of the ontogeny of V2- apex antibodies have led to increased 
efforts to incorporate structural and virological findings into targeted 
immunogens. Many clinical trials based on immunization with mono-
meric gp120 have failed to elicit bNAbs, including those directed to 
the V2- apex.82 The structural explanation for this latter finding is that 
such gp120 monomers do not form the full V2- apex epitope and can 
adopt multiple conformations of C strand.62 Scaffolded V1V2 designs 
offer immunogens that are advantageous in their ability to focus the 
immune response to a specific domain. However, there are a number 
of limitations for these constructs. Many are overexpressed in cells 
where the glycosylation machinery becomes overwhelmed, resulting 
in heterogeneously glycosylated sites. These results are evident from 
ladders of differentially glycosylated scaffold bands on an SDS PAGE 
gel.55 Additionally, a substantial proportion of scaffolds do not fold 
properly. These two issues could be overcome through on- column 
purification methods, where misfolded or improperly glycosylated 
molecules flow past the antibody and only those that are suitable 
immunogens are bound, resulting in a homogeneous population of 
antibody- bound scaffolds. If these scaffolds could be removed from 
the bound antibody without disturbing the scaffolded structure then 
they could be used as monomeric immunogens. However, the remain-
ing, and possibly most important, limitation is that no published scaf-
folds correctly recapitulate the full trimeric orientation of a properly 
folded native trimer.
The advance of soluble trimers such as BG505 SOSIP.664 has 
overcome many of the obstacles associated with monomeric immuno-
gens and therefore marks a critical and exciting advance toward target-
ing V2- directed bNAbs. The quaternary nature of V2- directed bNAbs 
elicited through natural infection strongly suggest that effective im-
munogens targeting this ontogeny need to present the full epitope 
present on the native viral spike. Availability of this soluble trimer has 
provided a great deal of structural information (described above) re-
cently enabling the optimization of immunogen design targeting spe-
cific epitopes, particularly those of a quaternary nature. Atomic- level 
details from multiple structural studies of this construct has facilitated 
F IGURE  5 Antibody maturation 
pathways and their implications for HIV 
vaccine design. (A) Schematic depicting 
how CAP256 viral evolution results in 
the engagement of the CAP256- VRC26 
UCA (light gray) and the subsequent 
development of two distinct mAb 
sublineages. The sublineage with restricted 
evolution contains dead- end mAbs (dark 
gray), which cannot tolerate viral escape 
mutations. The continually evolving 
sublineage contains bNAbs (red) and 
off- track mAbs (turquoise). Although both 
bNAbs and off- track mAbs have high 
levels of SHM, only the former mature to 
recognize multiple immunotypes, and thus 
acquire breadth. Adapted from (69) (B) 
Schematic depicting a vaccine approach 
that seeks to recapitulate key viral events 
that drove neutralization breadth in the 
CAP256- VRC26 lineage by the use of 
sequential or cocktail approaches. Adapted 
from (69)
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additional stabilizing mutations such as a disulfide between residues 
201 and 433 that prevents the trimer from conformationally shifting 
upon binding of CD4. However, providing a stabilized architecture of 
the trimeric V1V2 epitope may not be sufficient to elicit a response. 
Effective immunogens must also take into account the distance and 
orientations of each V1V2 domain relative to each other, the equi-
librium of the domain at the cap (the V1V2 domain may shift as ob-
served by smFRET83), stabilization of the C- strand itself, exact residue 
requirements, and the appropriate glycosylation. Without the right 
strain there is very little chance of engagement even if the appropriate 
antibody precursor is present. Critically, as mentioned above, precur-
sors to V2 bNAbs do not neutralize or bind the vast majority of naïve 
strains.57, 67–69, 79 This suggests that, even if the precursors exist in a 
naive repertoire and a soluble trimer that perfectly recapitulates the 
native spike is present, V2 bNAb precursors are unlikely to be stimu-
lated unless the appropriate strains are used.
The identification of a few strains that have a higher  probability of 
engaging V2- apex bNAb precursors from multiple donors,  described 
above,57, 79 opens up possibilities for incorporating these into trimeric 
immunogens. However, the use of these viral strains to elicit V2- apex 
bNAbs still includes a number of obstacles. The SOSIP mutations that 
are used to stabilize soluble trimers such as BG505 SOSIP.664, have 
been now been integrated into a small number of additional strains to 
form soluble trimers,66, 84–86 and similarly a few strains form  stable tri-
mers with a set of mutations termed NFL.87 However, most strains are 
unstable or do not display full cleavage,63, 84 thereby resulting in trimers 
with heterogeneous protomers which can unfavorably alter their anti-
genic profile. Several solutions are currently available such as  replacing 
the V1V2 domain (residues 126- 196) of the BG505 SOSIP.664 with 
those of the strain of interest.57 This strategy requires that the V3- V1V2 
interactions be compatible between strains. Alternatively, the entire 
gp120 may be replaced while maintaining core residues of BG505 in 
the N and C termini, as well as gp41 (M.G. Joyce et al., unpublished). 
One attractive alternative is to remove the cleavage site altogether: 
this can be accomplished through placing a flexible peptide linker in 
its place88, 89 although this method requires additional stabilization of 
other regions. This method does occlude a target site of vulnerability 
in the fusion peptide,41 however, if the goal is to target V1V2 bNAbs 
specifically, this is not a critical epitope to retain. The great advantage 
of this method as a vaccine strategy is that it removes the requirement 
for furin co- expression, which simplifies the manufacturing pathway for 
stable soluble protein. This provides a means of delivering optimized 
cleavage- independent trimers, which could easily be engineered to in-
corporate the multiple immunotypes required for the development of 
breadth during natural infection, via genetic immunizations.
9  | CONCLUSIONS
With the availability of a soluble trimer that mimics that native spike, 
a great many ideas for immunogen design that were technologically 
unavailable just a few years ago are now possible. An explosion of 
crystal and EM structures56, 57, 64–66 has also provided atomic- level 
details to further stabilize the molecules. Replacement of the V1V2 
domain or design of gp120 chimeras which require an understand-
ing of the atomic- level details of the trimeric interactions are possible 
now that structures of the trimers are available. Recent advances have 
also been achieved in structurally defining the glycan shield surround-
ing the trimer that must be accounted for by V2 bNAbs. Additionally, 
technology to assemble these trimers onto nanoparticles is still under 
development but the field is moving forward at an extraordinary pace 
with these new tools. Open questions still remain regarding the exact 
mechanism of how specific strains are engaged by V2 bNAb precur-
sors, what the optimal glycan requirements are for eliciting bNAbs 
and whether vaccine strategies need to incorporate diversity (and if so 
how much) to drive antibodies toward breadth, as suggested by stud-
ies of infection. However, stabilized trimers presenting the appropri-
ate quaternary epitope for stimulating V2 bNAb precursors represent 
one of the most exciting immunogen strategies, and has only become 
possible with the through our recent understanding of these antibody 
ontogenies as well as the emergence of sophisticated soluble trimeric 
reagents in the past few years.
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